Figure 2From: Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysisEffect sizes based on mean change from baseline at Week 26 on individual SIB items. SIB, Severe Impairment Battery. Analysis based on the Intent-To-Treat Last Observation Carried Forward (ITT-LOCF) population. Negative change scores indicate deterioration.Back to article page